Validating a Comprehensive R&D System and Pioneering New Frontiers in Combination Therapies | Jeyou Pharma’s First Class 1 Innovative Drug, Jielemei®, Approved for Market Launch

[Introduction] Delivering significant clinical value and ushering in a new era of differentiated competition. Shanghai Jeyou Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Jeyou Pharma”) announced today that the National Medical Products Administration (NMPA) has officially approved the market launch of Jielemei® (suximerex sulfate tablets), the company’s independently developed KRAS G12C inhibitor. As the company’s first self-developed product since its inception, the approval of Jilemei® not only provides domestic patients with KRAS G12C-mutated non-small cell lung cancer with a new treatment option that is “once-daily, more effective, and more convenient,” but also signifies that Jeyou Pharma has successfully demonstrated its capabilities across the entire R&D process—from “molecular design” to “market approval”—laying a solid foundation for the differentiated advancement of its future pipeline.